Tocilizumab therapy and COVID-19
- PMID: 34388326
- DOI: 10.1515/jom-2021-0181
Tocilizumab therapy and COVID-19
Comment in
-
Response to "Tocilizumab therapy and COVID-19".J Osteopath Med. 2021 Sep 8;121(11):867-868. doi: 10.1515/jom-2021-0212. J Osteopath Med. 2021. PMID: 34492174 No abstract available.
Comment on
-
The role of tocilizumab therapy in critically ill patients with severe acute respiratory syndrome coronavirus 2.J Osteopath Med. 2021 Jul 12;121(8):705-714. doi: 10.1515/jom-2020-0292. J Osteopath Med. 2021. PMID: 34237804
References
-
- Saffo, Z, Guo, W, Springer, K, Maksimowicz-McKinnon, K, Kak, V, McKinnon, JE, et al.. The role of tocilizumab therapy in critically ill patients with severe acute respiratory syndrome coronavirus 2. J Osteopath Med 2021;121:705–14. https://doi.org/10.1515/jom-2020-0292.
-
- Richier, Q, Jachiet, V, Bonnemains, V, Plaçais, L, Abisror, N, Garnier, M, et al.. Tocilizumab and COVID-19: timing of administration assessment. Infect Dis Now 2021;S2666–9919:420–6. https://doi.org/10.1016/j.idnow.2021.06.304.
-
- Fu, B, Xu, X, Wei, H. Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med 2020;18:164. https://doi.org/10.1186/s12967-020-02339-3.
-
- Rugberg, W, Mishra, S, Rajput, R. Tociliumab for patients admitted with COVID-19 pneumonia. Adv Trop Med Public Health Int 2021;11:17–8.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources